Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ENDO HEALTH SOLUTIONS INC. | d353283d8k.htm |
 1
Exhibit 99.1 |
 2
Forward Looking Statements
This
presentation
contains
forward-looking
statements
within
the
meaning
of
the
Private
Securities
Litigation
Reform
Act
of
1995.
Statements
including
words
such
as
“believes,”
“expects,”
“anticipates,”
“intends,”
“estimates,”
“plan,”
“will,”
“may,”
“look
forward,”
“intend,”
“guidance,”
“future”
or
similar
expressions
are
forward-looking
statements.
Because
these
statements
reflect
our
current
views,
expectations
and
beliefs
concerning
future
events,
these
forward-looking
statements
involve
risks
and
uncertainties.
Investors
should
note
that
many
factors,
as
more
fully
described
under
the
caption
“Risk
Factors”
in
our
Form
10-K,
Form
10-Q
and
Form
8-K
filings
with
the
Securities
and
Exchange
Commission
and
as
otherwise
enumerated
herein
or
therein,
could
affect
our
future
financial
results
and
could
cause
our
actual
results
to
differ
materially
from
those
expressed
in
forward-looking
statements
contained
in
our
Annual
Report
on
Form
10-K.
The
forward-looking
statements
in
this
presentation
are
qualified
by
these
risk
factors.
These
are
factors
that,
individually
or
in
the
aggregate,
could
cause
our
actual
results
to
differ
materially
from
expected
and
historical
results.
We
assume
no
obligation
to
publicly
update
any
forward-looking
statements,
whether
as
a
result
of
new
information,
future
developments
or
otherwise.
©2012 Endo Pharmaceuticals Holdings Inc. |
 Solutions for 21
st
Century Healthcare
I.
Our Diversified Business
II.
2012 Growth Drivers
III.
Commitment to Innovation
IV.
2012 Financial Guidance
V.
Summary
©2012 Endo, Inc. All rights reserved.
3 |
 Solid
Track Record of Sales Growth Endo expects to report more than $3 Billion in
2012 sales 4
©2012 Endo Pharmaceuticals Holdings Inc. |
 Strong Cash Flow Generation
5
©2012 Endo Pharmaceuticals Holdings Inc. |
 Diversified Healthcare Solutions Company
6
*Pro
forma
-
Includes
full
year
of
AMS.
**The
services
segment
does
not
include
the
pro
forma
impact
of
pre-acquisition
revenues
from
the
recently
acquired
electronic
medical
records
providers,
Intuitive
Medical
Software
(IMS)
and
meridian
EMR,
Inc.
©2012 Endo Pharmaceuticals Holdings Inc. |
 2012
Performance – Positioned for Strong Second Half
7
•
Anticipate strong second half 2012 driven by
revenue growth opportunities across all segments
•
Expect expense to revenue ratios to decrease
significantly from combination of revenue growth
and expense management
©2012 Endo Pharmaceuticals Holdings Inc. |
 Growth Driver for Second Half 2012 –
OPANA
®
ER
8
•
Announced return to promotional activities on May 1
•
Expect rebuild of inventory in Q2
•
Strong formulary position
•
Patent protection through 2029
•
57% of TRx for Opana ER
filled with new formulation
•
IMS Health data
•
Week ending May 4, 2012
©2012 Endo Pharmaceuticals Holdings Inc. |
 Growth Driver for Second Half 2012 –
Voltaren
®
Gel
9
•
Announced return to promotional activities on May 1
•
Rebuild of inventory expected late-Q2 or early-Q3
•
Expect to return to growth in the second half of 2012
©2012 Endo Pharmaceuticals Holdings Inc. |
 Commitment to Innovation
10
©2012 Endo Pharmaceuticals Holdings Inc. |
 2012
Guidance 11
Guidance
Revenue range
$3.15B -
$3.30B
Adjusted diluted EPS range
$5.00 -
$5.20
Reported (GAAP) diluted EPS range
$1.75 -
$1.95
©2012 Endo Pharmaceuticals Holdings Inc. |
 2012
Value Creation Opportunities 12
•
Successfully launch new formulation of OPANA ER
•
Support the future growth of Qualitest
o
Invest capital to capture growing demand for products
o
Exceed cost synergies assumed at time of Qualitest acquisition
•
Invest in AMS to accelerate growth
o
Scale successful AMS/Endo pilot programs
o
Invest in R&D to accelerate advance of new products to market
•
Maximize operating cash flow to pay down debt
o
Have completed ~$500M of cumulative debt repayments on our
existing Term Loan indebtedness
©2012 Endo Pharmaceuticals Holdings Inc. |
 ©2012 Endo, Inc. All rights reserved.
13
*
*
*
*
*
* |
 14
Reconciliation of Non-GAAP Measures
For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s
Current Report on Form 8-K filed today with the Securities and Exchange
Commission Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted
Diluted Earnings Per Share Guidance for the Year Ending December 31, 2012 Lower End of
Range Upper End of Range
Projected GAAP diluted income per common share
$1.75
$1.95
Upfront and milestone-related payments to partners
$0.71
$0.71
Amortization of commercial intangible assets and inventory step-up
$1.87
$1.87
Acquisition and integration costs related to recent acquisitions.
$0.29
$0.29
One-time payment now expected to be made to Impax Labs
$0.90
$0.90
Impairment of long-lived assets
$0.33
$0.33
Interest expense adjustment for ASC 470-20 and other treasury items
$0.21
$0.21
Tax effect of pre-tax adjustments at the applicable tax rates and certain other
expected cash tax savings as a result of recent acquisitions
($1.06)
($1.06)
Diluted adjusted income per common share guidance
$5.00
$5.20
The company's guidance is being issued based on certain assumptions including:
•Certain of the above amounts are based on estimates and there
can be no assurance that Endo will achieve these results
•Includes all completed business development transactions as of
May 16, 2012 ©2012 Endo
Pharmaceuticals Holdings Inc. |
 |